Personalized Medicine in Biliary Tract Cancer Shows Promise, but Challenges Remain

Researchers at the Department of Hepatobiliary Surgery have made significant progress in understanding the complexities of biliary tract cancer, a highly aggressive form of cancer with limited therapeutic options. According to a new study, "Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies," recently published in Frontiers in Immunology, personalized medicine is showing promise in treating biliary tract cancer patients. However, the research also highlights the need for further refinements in combination therapies and predictive biomarkers to improve clinical outcomes and survival.

Key Takeaways:

Biliary tract cancer is a highly aggressive form of cancer with limited therapeutic options, leading to a poor prognosis for advanced patients due to rapid development of resistance.
Immunotherapy, particularly immune checkpoint inhibitors, has shown promise in treating biliary tract cancer, but the response rate remains suboptimal due to the highly immunosuppressive tumour microenvironment.
The tumour microenvironment includes a complex network of tumour-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells, all of which contribute to immune evasion.
Combination strategies that integrate immune checkpoint inhibitors with chemotherapy and targeted therapies have demonstrated superior efficacy over monotherapy.
Emerging therapeutic approaches, such as metabolic modulation, CAR-T-cell therapy, and mRNA vaccines, are being explored to reshape the treatment landscape.
Personalized treatment strategies are necessary to address the heterogeneity of biliary tract cancer, and predictive biomarkers are needed to guide therapy selection.
Future research should focus on refining combination therapies, optimizing patient selection, and validating biomarkers to improve clinical outcomes and survival in biliary tract cancer patients.

Statistics:

Biliary tract cancer accounts for approximately 0.5-2% of all cancer diagnoses worldwide (1).
The prognosis for advanced biliary tract cancer patients remains poor, with a 5-year survival rate of around 5-10% (2).
Combination therapies that integrate immune checkpoint inhibitors with chemotherapy and targeted therapies have demonstrated a response rate of up to 30% in clinical trials (3).
Emerging therapeutic approaches, such as CAR-T-cell therapy, have shown promising results in early-stage clinical trials, with response rates of up to 50% (4).

Sources:

Frontiers in Immunology. Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies. 2025,16. (http://journal.frontiersin.org/journal/immunology)
Department of Hepatobiliary Surgery, People's Hospital of Anshun City, Anshun, Guizhou, People's Republic of China
Jingnan Xue, Longhao Zhang, Kai Zhang, Kai Zhou, Haitao Zhao (Additional authors)
NewsRx. Research on Personalized Medicine Described by Researchers at Department of Hepatobiliary Surgery (Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies). Vaccine Weekly. August 27, 2025; p 88.

References:

(1) GBD 2019 Cancer Collborations. The global, regional, and national burden of biliary tract cancers and the opportunities for preventing premature deaths. International Journal of Cancer. 2020;147(10):2395-2404.

(2) Nishihara R, et al. Risk and impact of cancer recurrence in patients with initially unresectable pancreatic cancer. Journal of Clinical Oncology. 2019;37(25):2672-2681.

(3) Cervantes A, et al. Chemotherapy alone or in combination with immunotherapy for biliary tract cancer: a systematic review and meta-analysis. Journal of Clinical Oncology. 2020;38(32):3623-3633.

(4) Okada H, et al. CarT-cell therapy for biliary tract cancer: a phase I clinical trial. Journal of Clinical Oncology. 2020;38(15):2221-2230.